Moreira JN - Search Results

1

Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.

Gomes-da-Silva LC, Simões S, Moreira JN. Gomes-da-Silva LC, et al. Among authors: moreira jn. Cell Mol Life Sci. 2014 Apr;71(8):1417-38. doi: 10.1007/s00018-013-1502-2. Epub 2013 Nov 13. Cell Mol Life Sci. 2014. PMID: 24221135 Free PMC article. Review.

2

Technology evaluation: LErafAON, NeoPharm.

Moreira JN, Simões S. Moreira JN, et al. Curr Opin Mol Ther. 2003 Oct;5(5):547-52. Curr Opin Mol Ther. 2003. PMID: 14601525

3

On the formulation of pH-sensitive liposomes with long circulation times.

Simões S, Moreira JN, Fonseca C, Düzgüneş N, de Lima MC. Simões S, et al. Among authors: moreira jn. Adv Drug Deliv Rev. 2004 Apr 23;56(7):947-65. doi: 10.1016/j.addr.2003.10.038. Adv Drug Deliv Rev. 2004. PMID: 15066754 Review.

4

Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells.

Fonseca C, Moreira JN, Ciudad CJ, Pedroso de Lima MC, Simões S. Fonseca C, et al. Among authors: moreira jn. Eur J Pharm Biopharm. 2005 Feb;59(2):359-66. doi: 10.1016/j.ejpb.2004.08.012. Eur J Pharm Biopharm. 2005. PMID: 15661509 Free article.

5

Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.

Moreira JN, Santos A, Simões S. Moreira JN, et al. Rev Recent Clin Trials. 2006 Sep;1(3):217-35. doi: 10.2174/157488706778250050. Rev Recent Clin Trials. 2006. PMID: 18473975 Review.

6

Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing.

Moreira JN, Santos A, Moura V, Pedroso de Lima MC, Simões S. Moreira JN, et al. J Nanosci Nanotechnol. 2008 May;8(5):2187-204. doi: 10.1166/jnn.2008.319. J Nanosci Nanotechnol. 2008. PMID: 18572631 Review.

7

Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer.

Santos A, Sarmento-Ribeiro AB, de Lima MC, Simões S, Moreira JN. Santos A, et al. Among authors: moreira jn. Cytometry A. 2008 Dec;73A(12):1165-72. doi: 10.1002/cyto.a.20634. Cytometry A. 2008. PMID: 18785266 Free article.

8

Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.

Pinto AC, Moreira JN, Simões S. Pinto AC, et al. Among authors: moreira jn. Cancer Chemother Pharmacol. 2009 Aug;64(3):445-54. doi: 10.1007/s00280-008-0892-6. Epub 2008 Dec 23. Cancer Chemother Pharmacol. 2009. PMID: 19104815

9

Efficient chemoenzymatic synthesis, cytotoxic evaluation, and SAR of epoxysterols.

Carvalho JF, Cruz Silva MM, Moreira JN, Simões S, Sá E Melo ML. Carvalho JF, et al. Among authors: moreira jn. J Med Chem. 2009 Jul 9;52(13):4007-19. doi: 10.1021/jm9003973. J Med Chem. 2009. PMID: 19473028 Free article.

10

Targeted lipoplexes for siRNA delivery.

Cardoso A, Trabulo S, Moreira JN, Düzgüneş N, de Lima MC. Cardoso A, et al. Among authors: moreira jn. Methods Enzymol. 2009;465:267-87. doi: 10.1016/S0076-6879(09)65014-X. Methods Enzymol. 2009. PMID: 19913172

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters